Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-304
2022-501987-16-00Phase 3Completed
- Sponsor
- Incyte
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Pulmonary squamous cell carcinoma and non-small cell lung cancer (NSCLC) comparing Retifanlimab + platinum-based chemotherapy with Placebo + platinum-based chemotherapy (2 arms). Primary endpoint: Overall survival. Started Oct 2020; status: completed.
02
Drugs
retifanlimab
03
Conditions
Pulmonary squamous cell carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501987-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501987-16-00.